Loading...
Please wait, while we are loading the content...
Similar Documents
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Pikman, Yana Alexe, Gabriela Roti, Giovanni Conway, Amy Saur Kratka, Amy Weintraub Lee, Emily Place, Andrew E. Kim, Sunkyu Saran, Chitra Modiste, Rebecca Weinstock, David M. Harris, Marian Kung, Andrew L. Silverman, Lewis R. Stegmaier, Kimberly |
| Copyright Year | 2015 |
| Abstract | Purpose: Although significant progress has been made in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), many patients will require additional therapy for relapsed/refractory disease. Cyclin D3 (CCND3) and CDK6 are highly expressed in T-ALL and have been effectively targeted in mutant NOTCH1-driven mouse models of this disease with a CDK4/6 small-molecule inhibitor. Combination therapy, however, will be needed for the successful treatment of human disease.Experimental Design: We performed preclinical drug testing using a panel of T-ALL cell lines first with LEE011, a CDK4/6 inhibitor, and next with the combination of LEE011 with a panel of drugs relevant to T-ALL treatment. We then tested the combination of LEE011 with dexamethasone or everolimus in three orthotopic mouse models and measured on-target drug activity.Results: We first determined that both NOTCH1-mutant and wild-type T-ALL are highly sensitive to pharmacologic inhibition of CDK4/6 when wild-type RB is expressed. Next, we determined that CDK4/6 inhibitors are antagonistic when used either concurrently or in sequence with many of the drugs used to treat relapsed T-ALL (methotrexate, mercaptopurine, asparaginase, and doxorubicin) but are synergistic with glucocorticoids, an mTOR inhibitor, and gamma secretase inhibitor. The combinations of LEE011 with the glucocorticoid dexamethasone or the mTOR inhibitor everolimus were tested in vivo and prolonged survival in three orthotopic mouse models of T-ALL. On-target activity was measured in peripheral blood and tissue of treated mice.Conclusions: We conclude that LEE011 is active in T-ALL and that combination therapy with corticosteroids and/or mTOR inhibitors warrants further investigation. Clin Cancer Res; 23(4); 1012-24. ©2016 AACRSee related commentary by Carroll et al., p. 873. |
| Starting Page | 1012 |
| Ending Page | 1024 |
| Page Count | 13 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://clincancerres.aacrjournals.org/content/clincanres/23/4/1012.full.pdf |
| PubMed reference number | 28151717v1 |
| Alternate Webpage(s) | https://doi.org/10.1158/1078-0432.CCR-15-2869 |
| DOI | 10.1158/1078-0432.ccr-15-2869 |
| Journal | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Volume Number | 23 |
| Issue Number | 4 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | ASPARAGINASE Acute lymphocytic leukemia Adrenal Cortex Hormones Cholecalciferol Dexamethasone Doxorubicin Drug Delivery Systems Drug Screening Assays, Antitumor LEE011 Leukemia, B-Cell Methotrexate Neuritis, Autoimmune, Experimental Patients Pharmacology Precursor Cell Lymphoblastic Leukemia Lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Published Comment Substance Abuse Detection everolimus gamma-Secretase lymphoblast mTOR Inhibitor mercaptopurine peripheral blood secretase |
| Content Type | Text |
| Resource Type | Article |
